



CERES F&D

*A subsidiary of Alteogen Inc.*

 ALTEOGEN Inc.

# Ceres F&D, Inc.

## Introduction

### **NOTICE Proprietary and Confidential**

This material is proprietary to CERES F&D Inc.. It contains confidential information which is solely the property of CERES F&D Inc.. This material shall not be used, reproduced, copied, disclosed, transmitted in whole or in part without consent of CERES F&D Inc..

# Overview of Ceres F&D Inc.



## BUSINESS TYPE

Manufacturer / Exporter

## CAPITAL (2020)

2,207mil ₩(Korean won)

## ESTABLISHED YEAR

Aug., 2018 (by Alteogen Inc.)

## CEO

Jimmy Son

## EMPLOYEE / R&D

51/ 22

## PRODUCTION CAPACITY

Vancomycin HCl 4 MT/year

Teicoplanin 200 kg/year

Tacrolimus 200 kg/year  
(400kg/year from 2021)

# Business Cycle

## Main Products

### • Antibiotics


Teicoplanin Sterile  
(EP/JP/IP/KP)

Vancomycin HCl Sterile  
(EP/USP/JP/IP/KP)

### • Immunosuppressants

Tacrolimus  
(EP/USP/JP/IP)


- On going to get CEP by EU
- On going to get PMDA approval by Japan
- On going to get USFDA approval





- Immunosuppressive Drugs**
  - Tacrolimus water soluble
  - Everolimus API
  - Sirolimus API
- Biological Drugs**
  - rec.human Hyaluronidase

# Antibiotic Products

## Vancomycin



## Teicoplanin




**Class:** Glycopeptide antibiotics

**Application:** Recommended for serious infections  
e.g. MRSA, endocarditis, meningitis, peritonitis, etc.

**Patents:** 11 patents registered in Korea and overseas  
8 for Vancomycin, 2 for Teicoplanin

# Immunosuppressant Product

## Tacrolimus



**Name:** Tacrolimus, FK506, Fujimycin

**Structure:** Polyketide macrolide lactone  
*\*impossible to make via chemical fusion*

**Production Strain:** *Streptomyces tsukubaensis*

**Patents:** 8 Total (Korea, Overseas, PCT)


**Mech. of Action:** Inhibits T-cell activation  
• Calcineurin inhibitor

**Application:** Immunosuppressant

- Prevent rejection of transplanted organs
- Treat atopic dermatitis
- Oral, topical, and injection

# R&D Pipeline

Immunosuppressant
<b>Tacrolimus H<sub>2</sub>O Soluble</b>
<b>Sirolimus API</b>
<b>Everolimus API (Cytotoxic API)</b>
<b>Antibody-Antibiotic Conjugate</b>
<b>Tergase / Diluase (Rec. human Hyaluronidase)</b> Developed by  ALTEOGEN Inc.



# Overview of Pipeline Substances

## Tacrolimus H<sub>2</sub>O Soluble

Immunosuppressant




For Skin

For Eyes


## Sirolimus API

Immunosuppressant



## Diluase (Medical Device)

Cumulus cell remover  
for IVF




## Tergase

Improves Drug Absorption



Applied uses, e.g. IVF

# Conclusion



***Thank you for your attention.***